Erlotinib Prevention of Oral Cancer (EPOC)

NCT00402779 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

303

Enrollment

OTHER

Sponsor class

Conditions

Oral Cancer

Interventions

DRUG: Erlotinib
DRUG: Placebo

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]